Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Infectious Disease Reports
Published in: Current Infectious Disease Reports 4/2015

01-04-2015 | Transplant and Oncology (M Ison and N Theodoropoulos, Section Editors)

Live Virus Vaccines in Transplantation: Friend or Foe?

Authors: Charlotte M. Verolet, Klara M. Posfay-Barbe

Published in: Current Infectious Disease Reports | Issue 4/2015

Login to get access

Abstract

Solid organ and hematopoietic stem cell transplant recipients may be exposed to diseases which may be prevented through live attenuated virus vaccines (LAVV). Because of their immunosuppression, these diseases can lead to severe complications in transplant recipients. Despite increasing evidence regarding the safety and effectiveness of certain LAVV, these vaccines are still contraindicated for immunocompromised patients, such as transplant recipients. We review the available studies on LAVV, such as varicella zoster, measles–mumps–rubella, influenza, yellow fever, polio, and Japanese encephalitis vaccines in transplant patients. We discuss the current recommendations and the potential risks, as well as the expected benefits of LAVV immunization in this population.
Literature
1.
Stark K, Gunther M, Schonfeld C, et al. Immunisations in solid-organ transplant recipients. Lancet. 2002;359:957–65.PubMed
2.
Wyplosz B, Van der Vliet D, Consigny PH, et al. Vaccinations for the traveling adult solid organ transplant recipient (excluding hematopoietic stem cell transplant recipients). Med Mal Infect. 2009;39:225–33.PubMed
3.
Shetty AK, Winter MA. Immunization of children receiving immunosuppressive therapy for cancer or hematopoietic stem cell transplantation. Ochsner J. 2012;12:228–43.PubMedCentralPubMed
4.
Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Hematol Oncol Clin North Am. 2011;25:101–16.PubMed
5.
Pirofski LA, Casadevall A. Use of licensed vaccines for active immunization of the immunocompromised host. Clin Microbiol Rev. 1998;11:1–26.PubMedCentralPubMed
6.
Kano H, Mizuta K, Sakakihara Y, et al. Efficacy and safety of immunization for pre- and post-liver transplant children. Transplantation. 2002;74:543–50.PubMed
7.
Kumar D. Immunizations following solid-organ transplantation. Curr Opin Infect Dis. 2014;27:329–35.PubMed
8.••
Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:309–18. Excellent updated review of the guidelines for vaccination of immunocompromised adults and children.PubMed
9.
Kumar D, Blumberg EA, Danziger-Isakov L, et al. Influenza vaccination in the organ transplant recipient: review and summary recommendations. Am J Transplant. 2011;11:2020–30.PubMed
10.
Kumar D, Morris MI, Kotton CN, et al. Guidance on novel influenza A/H1N1 in solid organ transplant recipients†. Am J Transplant. 2010;10:18–25.PubMed
11.
Parham P. The immune system. Garland Science. 2009; third edition: 455.
12.
13.
Plotkin SA. Vaccines, vaccination, and vaccinology. J Infect Dis. 2003;187:1349–59.PubMed
14.
Danziger-Isakov L, Evans HM, Green M, et al. Capacity building in pediatric transplant infectious diseases: an international perspective. Pediatr Transplant. 2014;18:790–3.PubMed
15.
Pittet LF, Posfay-Barbe KM. Immunization in transplantation: review of the recent literature. Curr Opin Organ Transplant. 2013;18(5):543–8.
16.
Lopez MJ, Thomas S. Immunization of children after solid organ transplantation. Pediatr Clin North Am. 2003;50:1435–49.PubMed
17.
Posfay-Barbe KM, Siegrist CA. Immunization and transplantation—what is new and what is coming? Pediatr Transplant. 2009;13:404–10.PubMed
18.
Diana A, Posfay-Barbe KM, Belli DC, et al. Vaccine-induced immunity in children after orthotopic liver transplantation: a 12-yr review of the Swiss national reference center. Pediatr Transplant. 2007;11:31–7.PubMed
19.
L'Huillier AG, Wildhaber BE, Belli DC, et al. Successful serology-based intervention to increase protection against vaccine-preventable diseases in liver-transplanted children: a 19-yr review of the Swiss national reference center. Pediatr Transplant. 2012;16:50–7.PubMed
20.
Burroughs M, Moscona A. Immunization of pediatric solid organ transplant candidates and recipients. Clin Infect Dis. 2000;30:857–69.PubMed
21.
Sester M, Gartner BC, Girndt M, et al. Vaccination of the solid organ transplant recipient. Transplant Rev (Orlando). 2008;22:274–84.
22.
Danziger-Isakov L, Posfay-Barbe KM. Optimal approach to immunization in pediatric solid organ transplantation. Pediatr Transplant. 2012;16:680–3.PubMed
23.
Shinjoh M, Miyairi I, Hoshino K, et al. Effective and safe immunizations with live-attenuated vaccines for children after living donor liver transplantation. Vaccine. 2008;26:6859–63.PubMed
24.
Ljungman P, Cordonnier C, Einsele H, et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2009;44:521–6.PubMed
25.
Machado CM. Reimmunization after hematopoietic stem cell transplantation. Expert Rev Vaccines. 2005;4:219–28.PubMed
26.
Ariza-Heredia EJ, Gulbis AM, Stolar KR, et al. Vaccination guidelines after hematopoietic stem cell transplantation: practitioners' knowledge, attitudes, and gap between guidelines and clinical practice. Transpl Infect Dis. 2014. doi:10.​1111/​tid.​12312.
27.
Avery RK. Immunizations in adult immunocompromised patients: which to use and which to avoid. Cleve Clin J Med. 2001;68:337–48.PubMed
28.
Pauksen K, Duraj V, Ljungman P, et al. Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation. Bone Marrow Transplant. 1992;9:427–32.PubMed
29.
Sauerbrei A, Prager J, Hengst U, et al. Varicella vaccination in children after bone marrow transplantation. Bone Marrow Transplant. 1997;20:381–3.PubMed
30.
Styczynski J, Gil L, Party EPDW. Prevention of infectious complications in pediatric HSCT. Bone Marrow Transplant. 2008;42 Suppl 2:S77–81.PubMed
31.
Inaba H, Hartford CM, Pei D, et al. Longitudinal analysis of antibody response to immunization in paediatric survivors after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2012;156:109–17.PubMedCentralPubMed
32.
Danziger-Isakov L, Kumar D, Practice ASTIDCo. Vaccination in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:311–7.PubMed
33.••
Posfay-Barbe KM, Pittet LF, Sottas C, et al. Varicella-zoster immunization in pediatric liver transplant recipients: safe and immunogenic. Am J Transplant. 2012;12:2974–85. A significant interventional study which measured both humoral and cell-mediated immunity to VZV immunization in pediatric liver transplant recipients.PubMed
34.
Office fédéral de la santé publique. Vaccination contre la varicelle. Recommandations dela Commission suisse pour les vaccinations (CSV) et de l’Office fédéral de la santé publique (OFSP). Bull OFSP. 2004;45:846–8.
35.
Feldhoff CM, Balfour Jr HH, Simmons RL, et al. Varicella in children with renal transplants. J Pediatr. 1981;98:25–31.PubMed
36.
Geel A, Zuidema W, van Gelder T, et al. Successful vaccination against varicella zoster virus prior to kidney transplantation. Transplant Proc. 2005;37:952–3.PubMed
37.
Fehr T, Bossart W, Wahl C, et al. Disseminated varicella infection in adult renal allograft recipients: four cases and a review of the literature. Transplantation. 2002;73:608–11.PubMed
38.
Furth SL, Neu AM, Sullivan EK, et al. Immunization practices in children with renal disease: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol. 1997;11:443–6.PubMed
39.
McGregor RS, Zitelli BJ, Urbach AH, et al. Varicella in pediatric orthotopic liver transplant recipients. Pediatrics. 1989;83:256–61.PubMed
40.
Weinstock DM, Boeckh M, Boulad F, et al. Postexposure prophylaxis against varicella-zoster virus infection among recipients of hematopoietic stem cell transplant: unresolved issues. Infect Control Hosp Epidemiol. 2004;25:603–8.PubMed
41.
Banovic T, Yanilla M, Simmons R, et al. Disseminated varicella infection caused by varicella vaccine strain in a child with low invariant natural killer T cells and diminished CD1d expression. J Infect Dis. 2011;204:1893–901.PubMed
42.
Prelog M, Zimmerhackl LB. Varicella vaccination in pediatric kidney and liver transplantation. Pediatr Transplant. 2010;14:41–7.PubMed
43.
Broyer M, Tete MJ, Guest G, et al. Varicella and zoster in children after kidney transplantation: long-term results of vaccination. Pediatrics. 1997;99:35–9.PubMed
44.
Mizuta K, Urahashi T, Ihara Y, et al. Varicella zoster virus disease after pediatric living donor liver transplantation: is it serious? Transplant Proc. 2012;44:780–3.PubMed
45.
Kraft JN, Shaw JC. Varicella infection caused by Oka strain vaccine in a heart transplant recipient. Arch Dermatol. 2006;142:943–5.PubMed
46.
Levitsky J, Te HS, Faust TW, et al. Varicella infection following varicella vaccination in a liver transplant recipient. Am J Transplant. 2002;2:880–2.PubMed
47.
Kotton CN. Immunization after kidney transplantation—what is necessary and what is safe? Nat Rev Nephrol. 2014;10(10):555–62.PubMed
48.
Weinberg A, Horslen SP, Kaufman SS, et al. Safety and immunogenicity of varicella-zoster virus vaccine in pediatric liver and intestine transplant recipients. Am J Transplant. 2006;6:565–8.PubMed
49.
Zamora I, Simon JM, Da Silva ME, et al. Attenuated varicella virus vaccine in children with renal transplants. Pediatr Nephrol. 1994;8:190–2.PubMed
50.
Chaves Tdo S, Lopes MH, de Souza VA, et al. Seroprevalence of antibodies against varicella-zoster virus and response to the varicella vaccine in pediatric renal transplant patients. Pediatr Transplant. 2005;9:192–6.PubMed
51.
Khan S, Erlichman J, Rand EB. Live virus immunization after orthotopic liver transplantation. Pediatr Transplant. 2006;10:78–82.PubMed
52.
Ljungman P, Wang FZ, Nilsson C, et al. Vaccination of autologous stem cell transplant recipients with live varicella vaccine: a pilot study. Support Care Cancer. 2003;11:739–41.PubMed
53.•
Sasadeusz J, Prince HM, Schwarer A, et al. Immunogenicity and safety of a two-dose live attenuated varicella vaccine given to adults following autologous hematopoietic stem cell transplantation. Transpl Infect Dis. 2014. doi:10.​1111/​tid.​12295. An interesting interventional study showing that the VZV vaccine is safe but not immunogenic when administered early after HSCT.PubMed
54.
Chou JF, Kernan NA, Prockop S, et al. Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT). Biol Blood Marrow Transplant. 2011;17:1708–13.PubMedCentralPubMed
55.
Kussmaul SC, Horn BN, Dvorak CC, et al. Safety of the live, attenuated varicella vaccine in pediatric recipients of hematopoietic SCTs. Bone Marrow Transplant. 2010;45:1602–6.PubMed
56.
Bhalla P, Forrest GN, Gershon M, et al. Disseminated persistent and fatal infection due to the vaccine strain (vOka) of varicella-zoster virus in an adult following stem cell transplantation. Clin Infect Dis. 2014; ciu970.
57.
Mullane KM, Winston DJ, Wertheim MS, et al. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults. J Infect Dis. 2013;208:1375–85.PubMed
58.
Avery RK, Michaels M. Update on immunizations in solid organ transplant recipients: what clinicians need to know. Am J Transplant. 2008;8:9–14.PubMed
59.
Naidus E, Damon L, Schwartz BS, et al. Experience with use of Zostavax® in patients with hematologic malignancy and hematopoietic cell transplant recipients. Am J Hematol. 2012;87:123–5.PubMed
60.•
Issa NC, Marty FM, Leblebjian H, et al. Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2014;20:285–7. A large interventional study looking at the Herpes Zoster vaccine immunization in HSCT patients.PubMed
61.
Hata A, Asanuma H, Rinki M, et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med. 2002;347:26–34.PubMed
62.
Redman RL, Nader S, Zerboni L, et al. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis. 1997;176:578–85.PubMed
63.
Stadtmauer EA, Sullivan KM, Marty FM, et al. A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood. 2014;124:2921–9.PubMedCentralPubMed
64.
Kalman S, Bakkaloglu SA, Ozkaya O, et al. Measles: a rare communicable disease in a child with renal transplantation. Pediatr Transplant. 2002;6:432–4.PubMed
65.
Gastanaduy PA, Redd SB, Fiebelkorn AP, et al. Measles—United States, January 1-May 23, 2014. MMWR Morb Mortal Wkly Rep. 2014;63:496–9.PubMed
66.
67.
Kidd IM, Booth CJ, Rigden SP, et al. Measles-associated encephalitis in children with renal transplants: a predictable effect of waning herd immunity? Lancet. 2003;362:832.PubMed
68.
Sternfeld T, Spori-Byrtus V, Riediger C, et al. Acute measles infection triggering an episode of liver transplant rejection. Int J Infect Dis. 2010;14:e528–30.PubMed
69.
Young MK, Nimmo GR, Cripps AW, et al. Post-exposure passive immunisation for preventing measles. Cochrane Database Syst Rev. 2014;4, CD010056.PubMed
70.
Baas MC, van Donselaar KA, Florquin S, et al. Mumps: not an innocent bystander in solid organ transplantation. Am J Transplant. 2009;9:2186–9.PubMed
71.
Mazariegos GV, Green M, Reyes J, et al. Rubella infection after orthotopic liver transplantation. Pediatr Infect Dis J. 1994;13:161–2.PubMedCentralPubMed
72.
Eyre TA, Pelosi E, McQuaid S, et al. Mumps virus encephalomyelitis in a 19-year old male patient with an undefined severe combined immunodeficiency post-haematopoietic bone marrow transplantation: a rare fatal complication. J Clin Virol. 2013;57:165–8.PubMed
73.
Campbell AL, Herold BC. Immunization of pediatric solid-organ transplantation candidates: immunizations in transplant candidates. Pediatr Transplant. 2005;9:652–61.PubMed
74.
Rand EB, McCarthy CA, Whitington PF. Measles vaccination after orthotopic liver transplantation. J Pediatr. 1993;123:87–9.PubMed
75.
Machado CM, Goncalves FB, Pannuti CS, et al. Measles in bone marrow transplant recipients during an outbreak in Sao Paulo, Brazil. Blood. 2002;99:83–7.PubMed
76.
Machado CM, de Souza VA, Sumita LM, et al. Early measles vaccination in bone marrow transplant recipients. Bone Marrow Transplant. 2005;35:787–91.PubMed
77.
Shaw PJ, Bleakley M, Burgess M. Safety of early immunization against measles/mumps/rubella after bone marrow transplantation. Blood. 2002;99:3486.PubMed
78.
Pauksen K, Linde A, Lonnerholm G, et al. Influence of the specific T cell response on seroconversion after measles vaccination in autologous bone marrow transplant patients. Bone Marrow Transplant. 1996;18:969–73.PubMed
79.
Cordero E, Manuel O. Influenza vaccination in solid-organ transplant recipients. Curr Opin Organ Transplant. 2012;17:601–8.PubMed
80.••
Ison MG. Influenza prevention and treatment in transplant recipients and immunocompromised hosts. Influenza Other Respir Viruses. 2013;7 Suppl 3:60–6. An excellent update on influenza's epidemiology, prevention through immunization, and antiviral prophylaxis and treatment in immunocompromised patients.PubMed
81.
Manuel O, Humar A, Berutto C, et al. Low-dose intradermal versus intramuscular trivalent inactivated seasonal influenza vaccine in lung transplant recipients. J Heart Lung Transplant. 2011;30:679–84.PubMed
82.
Manuel O, Humar A, Chen MH, et al. Immunogenicity and safety of an intradermal boosting strategy for vaccination against influenza in lung transplant recipients. Am J Transplant. 2007;7:2567–72.PubMed
83.
Ambrose CS, Walker RE, Connor EM. Live attenuated influenza vaccine in children. Semin Pediatr Infect Dis. 2006;17:206–12.PubMed
84.
Office fédéral de la santé publique, Commission fédérale pour les vaccinations (CFV), Groupe de travail Influenza (GTI). Directives et recommandations. Recommandations pour la vaccination contre la grippe. Berne: Office Fédéral de la Santé Publique, 2011.
85.
Moore DL, Canadian Paediatric Society ID. Immunization C. Vaccine recommendations for children and youth for the 2014/2015 influenza season. Paediatr Child Health. 2014;19:440–4.PubMedCentralPubMed
86.
Committee On Infectious D, Committee On Infectious D. Recommendations for prevention and control of influenza in children, 2014-2015. Pediatrics. 2014;134:e1503–19.
87.
Abuali MM, Arnon R, Posada R. An update on immunizations before and after transplantation in the pediatric solid organ transplant recipient. Pediatr Transplant. 2011;15:770–7.PubMed
88.
Vermeiren P, Aubert V, Sugamele R, et al. Influenza vaccination and humoral alloimmunity in solid organ transplant recipients. Transpl Int. 2014;27:903–8.PubMed
89.
Candon S, Thervet E, Lebon P, et al. Humoral and cellular immune responses after influenza vaccination in kidney transplant recipients. Am J Transplant. 2009;9:2346–54.PubMed
90.
Gowda R, Cartwright K, Bremner JA, et al. Yellow fever vaccine: a successful vaccination of an immunocompromised patient. Eur J Haematol. 2004;72:299–301.PubMed
91.
Slifka MK, Hammarlund E, Lewis MW, et al. Antiviral immune response after live yellow fever vaccination of a kidney transplant recipient treated with IVIG. Transplantation. 2013;95:e59–61.PubMedCentralPubMed
92.
Monath TP, Vasconcelos PF. Yellow fever. J Clin Virol. 2014;S1386–6532(14):00369–2.
93.
Gerasimon G, Lowry K. Rare case of fatal yellow fever vaccine-associated viscerotropic disease. South Med J. 2005;98:653–6.PubMed
94.
Vasconcelos PF, Luna EJ, Galler R, et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet. 2001;358:91–7.PubMed
95.
Yax JA, Farnon EC, Cary EN. Successful immunization of an allogeneic bone marrow transplant recipient with live, attenuated yellow fever vaccine. J Travel Med. 2009;16:365–7.PubMed
96.
Barte H, Horvath TH, Rutherford GW. Yellow fever vaccine for patients with HIV infection. Cochrane Database Syst Rev. 2014;1, CD010929.PubMed
97.
Pistone T, Verdiere CH, Receveur MC, et al. Immunogenicity and tolerability of yellow fever vaccination in 23 French HIV-infected patients. Curr HIV Res. 2010;8:461–6.PubMed
98.
Kengsakul K, Sathirapongsasuti K, Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai. 2002;85:131–4.PubMed
99.
Azevedo LS, Lasmar EP, Contieri FL, et al. Yellow fever vaccination in organ transplanted patients: is it safe? A multicenter study. Transpl Infect Dis. 2012;14:237–41.PubMed
100.
Who. Polio vaccines: WHO position paper, January 2014—recommendations. Vaccine. 2014;32:4117–8.
101.
Prevots DR, Burr RK, Sutter RW, et al. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49:1–22. quiz CE21-27.PubMed
102.
Yun SI, Lee YM. Japanese encephalitis: the virus and vaccines. Hum Vaccine Immunother. 2014;10:263–79.
103.
Organization WH. Japanese encephalitis surveillance and immunization—Asia and the western Pacific 2012. MMWR Morb Mortal Wkly Rep. 2013;62:658–62.
104.
Griffiths MJ, Turtle L, Solomon T. Japanese encephalitis virus infection. Handb Clin Neurol. 2014;123:561–76.PubMed
105.
Hennessy S, Liu Z, Tsai TF, et al. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. Lancet. 1996;347:1583–6.PubMed
106.
Tsai TF, Yu YX, Jia LL, et al. Immunogenicity of live attenuated SA14-14-2 Japanese encephalitis vaccine—a comparison of 1- and 3-month immunization schedules. J Infect Dis. 1998;177:221–3.PubMed
107.•
Pakakasama S, Wattanatitan S, Techasaensiri C, et al. Immunogenicity of a live-attenuated Japanese encephalitis vaccine in children and adolescents after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2014;49:1307–9. The first interventional study on JE (SA 14-14-12) immunization in transplant patients.PubMed
108.
Lerchenfeldt SM, Cronin SM, Chandrasekar PH. Vaccination adherence in hematopoietic stem cell transplant patients: a pilot study on the impact of vaccination cards and reminder telephone calls. Transpl Infect Dis. 2013;15:634–8.PubMed
109.
Ljungman P, Fridell E, Lonnqvist B, et al. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis. 1989;159:610–5.PubMed
110.
King SM, Saunders EF, Petric M, et al. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients. Bone Marrow Transplant. 1996;17:633–6.PubMed
Metadata
Title
Live Virus Vaccines in Transplantation: Friend or Foe?
Authors
Charlotte M. Verolet
Klara M. Posfay-Barbe
Publication date
01-04-2015
Publisher
Springer US
Published in
Current Infectious Disease Reports / Issue 4/2015
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-015-0472-y

Other articles of this Issue 4/2015

Current Infectious Disease Reports 4/2015 Go to the issue

HIV/AIDS (R MacArthur, Section Editor)

What We Know and What We Do Not Know About Factors Associated with and Interventions to Promote Antiretroviral Adherence

Central Nervous System Infections (J Lyons, Section Editor)

Imaging in Neurologic Infections II: Fungal and Viral Diseases

Transplant and Oncology (M Ison and N Theodoropoulos, Section Editors)

The Challenges and Promise of HIV-Infected Donors for Solid Organ Transplantation

Healthcare Associated Infections (G Bearman, Section Editor)

Hand Hygiene Compliance Monitoring: the State of the Art

Transplant and Oncology (M Ison and N Theodoropoulos, Section Editors)

Value of Solid Organ Transplant-Trained Pharmacists in Transplant Infectious Diseases

Transplant and Oncology (M Ison and N Theodoropoulos, Section Editors)

Transplant Tourism: Understanding the Risks
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits